Articles

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

Konstantinos Arnaoutakis, MD, discusses pivotal updates in stage III disease, immunotherapy combinations in advanced non–small cell lung cancer, and advances in EGFR- and ALK-mutated lung cancer.

Leading Oncologist Highlights Key Lung Cancer Advances

Matthew Steliga, MD, discusses key surgical updates in lung cancer and the shifting role of surgery with the emergence of novel therapies.

Novel Surgical Strategies at the Forefront in Lung Cancer

Mollie Meek, MD, highlights key lung cancer screening trials, offered insight into how to successfully implement an effective program, and stressed that collaboration is critical in order to provide the best patient care.

UAMS Winthrop Cancer Institute

Latest from UAMS Winthrop Cancer Institute

New content coming soon, please check back later.